2018 International Congress

Monday, October 8, 2018

1:15pm-2:45pm

Plasma levels of vitamin D in patients with Parkinson’s disease: Correlation with Mini Mental State Examination and disease duration

M. Barichella, L. Lorio, C. Bolliri, A. Giana, V. Ferri, G. Pinelli, E. Cassani, S. Caronni, C. Esposito, G. Riboldazzi, A. Maras, A. Perretti, F. Del Sorbo, P. Amadeo, R. Cilia, E. Cereda, G. Pezzoli (Milan, Italy)

Parkinson's Disease: Cognition  ·  Hall 3FG

1:15pm-2:45pm

Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease

I. Mironova, A. Latypova, I. Zhukova, O. Izhboldina, E. Kolupaeva, N. Zhukova, S. Ivanova (Tomsk, Russian Federation)

Parkinson's Disease: Genetics  ·  Hall 3FG

1:15pm-2:45pm

Potential indicator of antiparkinsonian drug efficacy: an attempt to explore imaging findings

S. Taguchi, N. Tanabe, H. Oiwa, M. Hayashi, C. Nagatomi, S. Saeki, K. Nakashima, T. Yuasa, A. Yasumoto, H. Ando, T. Higa, A. Fujikake, T. Fukuoka, K. TokuI, Y. Okada, J. Niwa, M. Izumi, N. Nakao, M. Doyu (Nagakute, Japan)

Parkinson's Disease: Neuroimaging And Neurophysiology  ·  Hall 3FG

1:15pm-2:45pm

Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure

S. Hegde, M. Pulido-Rios, A. McNamara, J. Smith, W. Smith, J. Kanodia, D. Bourdet (South San Francisco, CA, USA)

Parkinson's Disease: Non-Motor Symptoms  ·  Hall 3FG

1:15pm-2:45pm

Predictive factors of fast cognitive decline in Parkinson’s disease after subthalamic stimulation: Myth or reality?

F. Fluchere, F. Ory-Magne, M. Anheim, V. Rousseau, A. Eusebio, O. Lagha Boukbiza, B. Lemesle, T. Witjas, N. Longato, C. Tranchant, C. Brefel-Courbon, JP. Azulay (Marseille, France)

Parkinson's Disease: Cognition  ·  Hall 3FG

1:15pm-2:45pm

Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up

S. Perez-Lloret, A. Sauerbier, C. Falup-Percurariu, M. Tinazzi, K.R. Chaudhuri (Buenos Aires, Argentina)

Parkinson's Disease: Non-Motor Symptoms  ·  Hall 3FG

1:15pm-2:45pm

Predictors of freezing of gait in newly diagnosed Parkinson’s disease: Clinical, dopamine transporter imaging and CSF markers in the PPMI cohort

R. Kim, J. Lee, H.J. Kim, A. Kim, B. Jeon, U.J. Kang, S. Fahn (Seoul, Republic of Korea)

Parkinson's Disease: Pathophysiology  ·  Hall 3FG

1:15pm-2:45pm

Prefrontal cortical stimulation to treat anxiety and depression in Parkinson’s disease

C. de Hemptinne, W. Chen, C. Racine, A. Seritan, A. Miller, J. Mergenthaler, S. Rajagopalan, J. Ostrem, M. San Luciano, P. Starr (San Francisco, CA, USA)

Parkinson's Disease: Pathophysiology  ·  Hall 3FG

1:15pm-2:45pm

Preliminary Results of Psychometric Properties of the Freezing of Gait Questionnaire in Turkish Patients with Parkinson’s Disease

E A. Ozturk, F. Nazli, B. Gonenli Kocer, S B. Tonuk, A. Can, N. Tezel, C. Uz, O. Ecerkale, F A. Cakci (Ankara, Turkey)

Rating Scales  ·  Hall 3FG

1:15pm-2:45pm

Preliminary Results of Psychometric Properties of the Turkish version of Falls Efficacy Scale – International in Patients with Parkinson’s Disease

F. Nazli, E A. Ozturk, B. Gonenli Kocer, S B. Tonuk, N. Tezel, A. Can, C. Uz, O. Ecerkale, F A. Cakci (Ankara, Turkey)

Rating Scales  ·  Hall 3FG